Keywords: fda, asks, lilly, submit, rems, olanzapine, lai

FDA asks Lilly to submit REMS on olanzapine LAI in complete response letter

Article | 12 January 2009

Print This

US drug major Eli Lilly has received a complete response letter from the Food and Drug Administration for olanzapine long-acting ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in